Role of the new oral hypoglycemic drugs in the diabetic patient with ESRD

Seminars in Dialysis

Volumn 12, Issue 1, 1999, Pages 25-31

  Williams, Mark E ^a   Roshan, Bijan ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 17944369428     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139X.1999.t01-5-00001.x     Document Type: Article

References (6)

1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
2. Incidence and Prevalence of ESRD: Primary disease, age, sex, and race for all patients, 1992-96; annualized change in Medicare ESRD incidence rates by primary diagnosis, 1991-96. USRDS Annual Data Report, NIH, Bethesda, MD 31-32, 1998
3. American Diabetes Association: Clinical practice recommendations 1998: Diabetic nephropathy. Care 21(Suppl 1):550-553, 1998
4. Olefsky JM: Introduction: Pathogenesis of insulin resistance and hyperglycemia in NIDDM. Am J Med 79(Suppl 3B):1-7, 1985
5. Erikson J, Franssila-Kallunci A, Edstrand A, et al: Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343, 1989
6. Kumar S, Boulton A, Beck-Nielsen H, et al: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709, 1996